Trastuzumab-associated cardiac events in the Persephone trial

Background: We report cardiac events in the Persephone trial which compares 6–12 months of adjuvant trastuzumab in women with confirmed HER2-positive, early-stage breast cancer. Methods: Clinical cardiac events were defined as any of the following: symptoms and/or signs of congestive heart failure (...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2016-12, Vol.115 (12), p.1462-1470
Main Authors: Earl, Helena M, Vallier, Anne-Laure, Dunn, Janet, Loi, Shrushma, Ogburn, Emma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian, Abraham, Jean, Wardley, Andrew, Cameron, David A, Miles, David, Gounaris, Ioannis, Plummer, Chris, Hiller, Louise
Format: Article
Language:English
Subjects:
692/308/2779/109
692/4019/592/75
692/699/67/1059/2325
692/699/67/1347
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - adverse effects
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer Research
Cancer therapies
Cardiac function
Clinical Study
Drug Resistance
Ejection fraction
Epidemiology
Heart Failure - chemically induced
Humans
Medical prognosis
Medical research
Metastasis
Middle Aged
Molecular Medicine
Oncology
Toxicity
Trastuzumab - adverse effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: We report cardiac events in the Persephone trial which compares 6–12 months of adjuvant trastuzumab in women with confirmed HER2-positive, early-stage breast cancer. Methods: Clinical cardiac events were defined as any of the following: symptoms and/or signs of congestive heart failure (CHF) and new or altered CHF medication. In addition, left ventricular ejection fraction (LVEF) was measured at baseline and then 3 monthly for 12 months. Results: A total of 2500 patients, aged 22–82, were included: 1251 randomised to 12 months and 1249 to 6 months of trastuzumab treatment. A total of 93% (2335/2500) received anthracyclines, 49% of these (1136/2335) with taxanes. Cardiotoxicity delayed treatment in 6% of 12-month and 4% of 6-month patients ( P =0.01), and stopped treatment early in 8% (96/1214) of 12-month and 4% (45/1216) of 6-month patients ( P
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.2016.357